Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Colorectal Neoplasms

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 83 articles: HTML format

Single Articles

November 2022
1. DOI H, Fujiwara M, Beppu N, Yokoyama H, et al
   Neoadjuvant Modified Short-course Radiotherapy for Stage IV Rectal Cancer.
   Anticancer Res. 2022;42:5587-5595.
   PubMed     Abstract available
   
   
   
2. YUEH TC, Hung YC, Lee HT, Yang MD, et al
   Role of Matrix Metallopeptidase-2 Genotypes in Taiwanese Patients With Colorectal Cancer.
   Anticancer Res. 2022;42:5335-5342.
   PubMed     Abstract available
   
   
   
3. YAMAUCHI N, Matsuda T, Sawad R, Hasegawa H, et al
   Clinical Significance of Early Recurrence After Curative Resection of Colorectal Cancer.
   Anticancer Res. 2022;42:5553-5559.
   PubMed     Abstract available
   
   
   
4. TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al
   Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases.
   Anticancer Res. 2022;42:5497-5505.
   PubMed     Abstract available
   
   
   
5. PARK YL, Cho SB, Park SY, Oh HH, et al
   Engulfment and Cell Motility 1 (ELMO1) Regulates Tumor Cell Behavior and Predicts Prognosis in Colorectal Cancer.
   Anticancer Res. 2022;42:5343-5355.
   PubMed     Abstract available
   
   
   
6. MEIROVITZ A, Baider L, Peretz T, Stephanos S, et al
   PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics.
   Anticancer Res. 2022;42:5487-5496.
   PubMed     Abstract available
   
   
   
7. TOMINAGA T, Nonaka T, Oyama S, Takamura Y, et al
   Gustave Roussy Immune Score for Predicting Postoperative Complications and Non-cancer Death in Elderly Patients With Colon Cancer.
   Anticancer Res. 2022;42:5643-5653.
   PubMed     Abstract available
   
   
   
8. KIM SH, Song SE, Baik H, Hur DY, et al
   15-Prostaglandin Dehydrogenase Inhibition Enhances Colon Cancer Metastasis by Up-regulation of Epithelial-to-Mesenchymal Transition Genes.
   Anticancer Res. 2022;42:5385-5396.
   PubMed     Abstract available
   
   
   October 2022
9. KATO S, Miyoshi N, Fujino S, Minami S, et al
   Combined Inflammation and Nutrition Factors Reinforce the Prognostic Prediction for Stage III Colorectal Cancer Patients.
   Anticancer Res. 2022;42:4989-4999.
   PubMed     Abstract available
   
   
   
10. CHOMICKI S, Chapet S, Drifa M, Ouaissi M, et al
    Outcomes and Side Effects of Preoperative Chemoradiotherapy for Locally Advanced Upper Rectal Cancer.
    Anticancer Res. 2022;42:4833-4840.
    PubMed     Abstract available
    
    
    
11. OZATO Y, Masuda T, Kobayashi Y, Takao S, et al
    PRKRIP1, A Splicing Complex Factor, Is a Marker of Poor Prognosis in Colorectal Cancer.
    Anticancer Res. 2022;42:4701-4706.
    PubMed     Abstract available
    
    
    
12. RYU S, Kitagawa T, Goto K, Okamoto A, et al
    Intraoperative Holographic Guidance Using Virtual Reality and Mixed Reality Technology During Laparoscopic Colorectal Cancer Surgery.
    Anticancer Res. 2022;42:4849-4856.
    PubMed     Abstract available
    
    
    
13. ZHU D, Guo P, Jin XY, Zhang R, et al
    Long-chain Non-coding RNA MIR4435-2HG Expression Correlates With Size of Intestinal Polyps in Children and With Metastasis of Colon Cancer.
    Anticancer Res. 2022;42:4707-4714.
    PubMed     Abstract available
    
    
    
14. CZAPLA J, Drzyzga A, Matuszczak S, Pilny E, et al
    The Complex Composition of Trans-resveratrol, Quercetin, Vitamin E and Selenium Inhibits the Growth of Colorectal Carcinoma.
    Anticancer Res. 2022;42:4763-4772.
    PubMed     Abstract available
    
    
    
15. UTSUMI M, Inagaki M, Kitada K, Tokunaga N, et al
    Lymphocyte-to-C-Reactive Protein Ratio Predicts Prognosis in Patients With Colorectal Liver Metastases Post-hepatic Resection: A Retrospective Study.
    Anticancer Res. 2022;42:4963-4971.
    PubMed     Abstract available
    
    
    
16. GERGER A, Eisterer W, Fuxius S, Bastian S, et al
    Retrospective Analysis of Treatment Pathways in Patients With BRAF(V600E)-mutant Metastatic Colorectal Carcinoma - MORSE(CRC).
    Anticancer Res. 2022;42:4773-4785.
    PubMed     Abstract available
    
    
    September 2022
17. RUBIO CA, Vieth M, Lang-Schwarz C
    Crypts in Asymmetric Branching in Patients With Ulcerative Colitis in Remission.
    Anticancer Res. 2022;42:4493-4497.
    PubMed     Abstract available
    
    
    
18. TAN C, Fisher OM, Huang L, Alzahrani N, et al
    Comparison of Microwave and Radiofrequency Ablation in the Treatment of Pulmonary Metastasis of Colorectal Cancer.
    Anticancer Res. 2022;42:4563-4571.
    PubMed     Abstract available
    
    
    
19. CRISTAUDO AT, Jennings SB, Morris DL
    Comparison of Proportion of Elevated Carcinoembryonic Antigen Levels in Patients With Appendiceal and Colorectal Adenocarcinoma: A Systematic Review and Meta-analysis.
    Anticancer Res. 2022;42:4217-4235.
    PubMed     Abstract available
    
    
    August 2022
20. KAWAMURA H, Honda M, Takano Y, Kinuta S, et al
    Prognostic Role of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Stage IV Colorectal Cancer.
    Anticancer Res. 2022;42:3921-3928.
    PubMed     Abstract available
    
    
    
21. KUBOTA Y, Han Q, Hamada K, Aoki Y, et al
    Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
    Anticancer Res. 2022;42:3857-3861.
    PubMed     Abstract available
    
    
    
22. YOSHIDA K, Nishi K, Ishikura S, Nakabayashi K, et al
    Cancer Spheroid Proliferation Is Suppressed by a Novel Low-toxicity Compound, Pyra-Metho-Carnil, in a Context-independent Manner.
    Anticancer Res. 2022;42:3993-4001.
    PubMed     Abstract available
    
    
    July 2022
23. KATAOKA S, Arita T, Konishi H, Yamamoto Y, et al
    The Role of Inflammation-associated microRNA-4257 as a Promoter of Malignancy in Colorectal Cancer.
    Anticancer Res. 2022;42:3349-3360.
    PubMed     Abstract available
    
    
    
24. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    Site-specific Performance of ColonView (CV) Fecal Immunochemical Test (FIT) With Differences Between Proximal and Distal Colorectal Adenoma.
    Anticancer Res. 2022;42:3557-3567.
    PubMed     Abstract available
    
    
    
25. MINAMI S, Miyoshi N, Fujino S, Kato S, et al
    The Geriatric Nutritional Risk Index as a Prognosis Predictor in Patients With Rectal Cancer Receiving Neoadjuvant Chemotherapy.
    Anticancer Res. 2022;42:3759-3766.
    PubMed     Abstract available
    
    
    
26. HIRAIDE T, Morita Y, Horikawa M, Sugiyama E, et al
    Saturated Fatty Acids in Cell Membrane Lipids Induce Resistance to 5-Fluorouracil in Colorectal Cancer Cells.
    Anticancer Res. 2022;42:3313-3324.
    PubMed     Abstract available
    
    
    June 2022
27. TOMINAGA T, Nonaka T, Oyama S, Takamura Y, et al
    Utility of Drain Fluid Culture and Gram Stain in Early Intervention for Occult Anastomotic Leakage in Colorectal Cancer.
    Anticancer Res. 2022;42:3091-3098.
    PubMed     Abstract available
    
    
    
28. OIKONOMAKIS I, Brodin D, Horer TM, Skoog P, et al
    Altered mRNA Expression Due to Rectal Perforation in a Porcine Model - A Pilot Study.
    Anticancer Res. 2022;42:2827-2833.
    PubMed     Abstract available
    
    
    May 2022
29. WU MH, Chen CH, Chen CP, Huang TL, et al
    Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan.
    Anticancer Res. 2022;42:2375-2382.
    PubMed     Abstract available
    
    
    
30. TAMAGAWA H, Aoyama T, Numata M, Kazama K, et al
    Impact of Infectious Complications on Survival and Recurrence of Patients With Stage II/III Colorectal Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2022;42:2763-2769.
    PubMed     Abstract available
    
    
    
31. SATO S, Mikayama YO, Shiozawa M, Nukada S, et al
    Chemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer.
    Anticancer Res. 2022;42:2625-2635.
    PubMed     Abstract available
    
    
    
32. SONODA H, Kitamura C, Kano K, Anzai H, et al
    Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer.
    Anticancer Res. 2022;42:2461-2468.
    PubMed     Abstract available
    
    
    
33. TANIOKA H, Shimada K, Tsuji A, Kochi M, et al
    Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
    Anticancer Res. 2022;42:2675-2681.
    PubMed     Abstract available
    
    
    
34. PETRAKIS G, Mantso T, Koukourakis MI, Panayiotidis MI, et al
    Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an In Vitro Model of Colorectal Carcinoma.
    Anticancer Res. 2022;42:2363-2374.
    PubMed     Abstract available
    
    
    April 2022
35. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    The ColonView (CV) Quick Test for Fecal Occult Blood Shows Significantly Higher Diagnostic Accuracy in Detecting Distal than Proximal Colorectal Cancer.
    Anticancer Res. 2022;42:1879-1891.
    PubMed     Abstract available
    
    
    
36. KATO A, Miyoshi N, Ohtsuru T, Sakai D, et al
    A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202).
    Anticancer Res. 2022;42:1859-1865.
    PubMed     Abstract available
    
    
    
37. HONG JK, Kim DY, Shin JS, Ryu YS, et al
    CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK/STAT Pathway in Colorectal Cancer.
    Anticancer Res. 2022;42:1813-1819.
    PubMed     Abstract available
    
    
    
38. ISHIZAKI T, Katsumata K, Enomoto M, Mazaki J, et al
    Predictors of Lateral Pelvic Lymph Node Metastasis in Advanced Low Rectal Cancer Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2022;42:2113-2121.
    PubMed     Abstract available
    
    
    
39. TACHIKAWA Y, Kawai K, Ozaki K, Nozawa H, et al
    CD133(+)HIF-1alpha(-) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer.
    Anticancer Res. 2022;42:2033-2043.
    PubMed     Abstract available
    
    
    
40. TOMITA K, Chiba N, Ochiai S, Gunji T, et al
    Prognostic Impact of N2 of the Primary Tumour in Surgical Resection for Colorectal Liver Metastases.
    Anticancer Res. 2022;42:1997-2001.
    PubMed     Abstract available
    
    
    
41. KARAM E, Sindayigaya R, Giger-Pabst U, Gabriel M, et al
    Impact of Modern Management Strategies on the Clinical Outcome of Patients With Low Rectal Cancer - A Retrospective, Monocentric Cohort Study.
    Anticancer Res. 2022;42:1949-1963.
    PubMed     Abstract available
    
    
    March 2022
42. MAEDA A, Takahashi H, Harata S, Watanabe K, et al
    The Interaction Between Cancer-associated Fibroblasts and Cancer Cells Enhances Bcl-xL and Mcl-1 in Colorectal Cancer.
    Anticancer Res. 2022;42:1277-1288.
    PubMed     Abstract available
    
    
    
43. MATSUMURA K, Yamamura K, Miyamoto H, Hara Y, et al
    Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
    Anticancer Res. 2022;42:1645-1651.
    PubMed     Abstract available
    
    
    
44. MATSUDA R, Kotsugi M, Nakase K, Morimoto T, et al
    Awake Craniotomy for Subcortical Brain Metastasis Beneath the Speech Center: A Technical Case Report.
    Anticancer Res. 2022;42:1641-1644.
    PubMed     Abstract available
    
    
    
45. KATAYAMA H, Tominaga T, Nonaka T, Araki M, et al
    Effect of Neoadjuvant Chemotherapy in Patients With Locally Advanced Rectal Cancer: A Multicenter Propensity Score-matched Analysis.
    Anticancer Res. 2022;42:1527-1533.
    PubMed     Abstract available
    
    
    
46. NACARKAHYA G, Borazan E, Horozoglu C, Yaylim I, et al
    Investigation of Long Non-coding RNAs H19 and LINC00675 in Colorectal Cancers in Terms of Histopathological Features and Correlations With Plasma Markers.
    Anticancer Res. 2022;42:1301-1306.
    PubMed     Abstract available
    
    
    February 2022
47. LIANG JA, Kuo YC, Chao KSC, Chen WT, et al
    High vs. Standard Radiotherapy Dose in Locally Advanced Rectal Adenocarcinoma Patients Treated With Neoadjuvant Long Course Chemoradiotherapy: A Population-based Study.
    Anticancer Res. 2022;42:1143-1150.
    PubMed     Abstract available
    
    
    
48. SHIRAISHI T, Ogawa H, Ozawa N, Suga K, et al
    Risk and Protective Factors for Postoperative Complications in Elderly Patients With Colorectal Cancer.
    Anticancer Res. 2022;42:1123-1130.
    PubMed     Abstract available
    
    
    
49. TOMIOKA K, Aoki T, Watanabe M, Enami Y, et al
    Increased Transumbilical Incision Complication Rates With Laparoscopic Colorectal Resection: A Single-center Propensity Score-matched Cohort Study.
    Anticancer Res. 2022;42:1115-1121.
    PubMed     Abstract available
    
    
    
50. DE FELICE F, Musio D, Iafrate F, Caponnetto S, et al
    Intensified Total Neoadjuvant Therapy Versus Intensified Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: A Propensity Score Matching Analysis.
    Anticancer Res. 2022;42:991-1000.
    PubMed     Abstract available
    
    
    
51. KOYAMA M, Osada E, Akiyama N, Eto K, et al
    Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells.
    Anticancer Res. 2022;42:837-844.
    PubMed     Abstract available
    
    
    
52. HAGIWARA T, Sugimoto K, Momose H, Irie T, et al
    CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
    Anticancer Res. 2022;42:697-707.
    PubMed     Abstract available
    
    
    
53. GO G, Park HJ, Lee JH, Yun CW, et al
    Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression.
    Anticancer Res. 2022;42:857-866.
    PubMed     Abstract available
    
    
    January 2022
54. HWANG J, Park A, Kim C, Yu D, et al
    Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells.
    Anticancer Res. 2022;42:589-598.
    PubMed     Abstract available
    
    
    
55. MIYOSHI K, Sato E, Katsumata K, Fukushima G, et al
    CD15(+) Bone Marrow-derived Cells Are Regulators of Immune Response in ARG1-producing Colorectal Cancer Cells.
    Anticancer Res. 2022;42:459-470.
    PubMed     Abstract available
    
    
    
56. MULLER O, Sindayigaya R, Chomicki S, Karam E, et al
    Prognostic Impact of Upfront Surgery for Locally Advanced Upper Rectal Adenocarcinoma.
    Anticancer Res. 2022;42:155-164.
    PubMed     Abstract available
    
    
    
57. MIYATA H, Akiyama Y, Iizuka A, Kondou R, et al
    Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software.
    Anticancer Res. 2022;42:419-427.
    PubMed     Abstract available
    
    
    
58. BRESCIA A, Muttillo EM, Angelicone I, Madaffari I, et al
    The Role of Indocyanine Green in Laparoscopic Low Anterior Resections for Rectal Cancer Previously Treated With Chemo-radiotherapy: A Single-center Retrospective Analysis.
    Anticancer Res. 2022;42:211-216.
    PubMed     Abstract available
    
    
    December 2021
59. SHIBUTANI M, En W, Okazaki Y, Kashiwagi S, et al
    The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
    Anticancer Res. 2021;41:6211-6216.
    PubMed     Abstract available
    
    
    
60. ZENG X, Zhang L, Jia S, Lin T, et al
    Effects of Circulating 25(OH)D Status in Advanced Colorectal Cancer Patients Undergoing Chemotherapy: A Systematic Review.
    Anticancer Res. 2021;41:5903-5912.
    PubMed     Abstract available
    
    
    
61. MATSUHASHI N, Takahashi T, Tanaka C, Yawata K, et al
    Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01).
    Anticancer Res. 2021;41:6247-6257.
    PubMed     Abstract available
    
    
    November 2021
62. MAZAKI J, Katsumata K, Ohno Y, Udo R, et al
    A Novel Predictive Model for Anastomotic Leakage in Colorectal Cancer Using Auto-artificial Intelligence.
    Anticancer Res. 2021;41:5821-5825.
    PubMed     Abstract available
    
    
    
63. KAWAMURA H, Honda M, Takiguchi K, Kamiga T, et al
    Clinical Impact of Primary Tumor Site in Stage IV Colorectal Cancer: A Statewide Cohort Study.
    Anticancer Res. 2021;41:5693-5702.
    PubMed     Abstract available
    
    
    
64. TAGO T, Katsumata K, Udou R, Kasahara K, et al
    Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases.
    Anticancer Res. 2021;41:5539-5547.
    PubMed     Abstract available
    
    
    
65. ISHIZAWA M, Hirayu A, Makishima M
    Zinc Inhibits Cadherin 1 Expression Induced by 1alpha,25-Dihydroxyvitamin D3 in Colon Cancer Cells.
    Anticancer Res. 2021;41:5453-5459.
    PubMed     Abstract available
    
    
    
66. SUZUMURA H, Tsuruta M, Okabayashi K, Shigeta K, et al
    BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy.
    Anticancer Res. 2021;41:5445-5452.
    PubMed     Abstract available
    
    
    
67. ROH SA, Kwon YH, Lee JL, Kim SK, et al
    SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability.
    Anticancer Res. 2021;41:5431-5444.
    PubMed     Abstract available
    
    
    
68. ADACHI Y, Yamamura K, Yumoto S, Higashi T, et al
    Far-advanced Colorectal Liver Metastases Successfully Managed With Modified ALPPS and Radiofrequency Ablation in Combination With Chemotherapy.
    Anticancer Res. 2021;41:5855-5861.
    PubMed     Abstract available
    
    
    
69. AKAHOSHI S, Yamamura K, Komohara Y, Yoshii D, et al
    A Case Report of Metachronous Multiple Adenosquamous Carcinoma of the Colon Over-expressing PD-L1 and a Literature Review.
    Anticancer Res. 2021;41:5847-5854.
    PubMed     Abstract available
    
    
    
70. FURUKAWA K, Onda S, Taniai T, Hamura R, et al
    Risk Factors and Overcoming Strategies of Surgical Site Infection After Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2021;41:5651-5656.
    PubMed     Abstract available
    
    
    
71. MASATSUNE S, Kimura K, Kashiwagi S, En W, et al
    Impact of Intraoperative Blood Loss and Blood Transfusion on the Prognosis of Colorectal Liver Metastasis Following Curative Resection.
    Anticancer Res. 2021;41:5617-5623.
    PubMed     Abstract available
    
    
    
72. OKAMOTO D, Matsuda T, Sawada R, Hasegawa H, et al
    Risk Factors for Complications Following Lateral Pelvic Lymph Node Dissection for Rectal Cancer.
    Anticancer Res. 2021;41:5599-5604.
    PubMed     Abstract available
    
    
    
73. MEKLIN J, Eskelinen M, Guimaraes DP, Selander T, et al
    The Automatically Analyzed (AA) ColonView (CV) Quick Test for Fecal Occult Blood Shows Higher Diagnostic Accuracy in Detection of Colorectal Adenoma than Visually Analyzed Tests.
    Anticancer Res. 2021;41:5517-5525.
    PubMed     Abstract available
    
    
    October 2021
74. SATO S, Shiozawa M, Nukada S, Iguchi K, et al
    Preoperative Pre-albumin Concentration as a Predictor of Short-term Outcomes in Elderly Patients With Colorectal Cancer.
    Anticancer Res. 2021;41:5195-5202.
    PubMed     Abstract available
    
    
    
75. ATSUMI Y, Numata M, Kazama K, Kawahara S, et al
    Can D3 Lymph Node Dissection for Patients With Colon Cancer With a Poor C-Reactive Protein/Albumin Ratio Improve Survival Outcomes?
    Anticancer Res. 2021;41:5097-5106.
    PubMed     Abstract available
    
    
    
76. MEKLIN J, Eskelinen M, Guimaraes DP, Selander T, et al
    The New Generation Immunochemical Test for Fecal Occult Blood (ColonView Quick Test) Shows a High Diagnostic Accuracy in Colorectal Cancer Detection.
    Anticancer Res. 2021;41:5071-5079.
    PubMed     Abstract available
    
    
    
77. NEUPANE P, Mimura K, Nakajima S, Okayama H, et al
    The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment.
    Anticancer Res. 2021;41:4895-4905.
    PubMed     Abstract available
    
    
    
78. TADA Y, Matsumi Y, Hara K, Miyauchi W, et al
    Infiltration of CD204-overexpressing Macrophages Contributes to the Progression of Stage II and III Colorectal Cancer.
    Anticancer Res. 2021;41:4857-4865.
    PubMed     Abstract available
    
    
    
79. MIYAMOTO S, Fukui T, Horitani S, Tanimura Y, et al
    Linker Threonine-phosphorylated Smad2/3 Is a Biomarker of Colorectal Neoplastic Stem-like Cells that Correlates With Carcinogenesis.
    Anticancer Res. 2021;41:4789-4799.
    PubMed     Abstract available
    
    
    
80. OZLUK E, Coppola D, Mohammad IZ, Islam T, et al
    Ethylmalonic Encephalopathy 1 Protein Is Increased in Colorectal Adenocarcinoma.
    Anticancer Res. 2021;41:4719-4723.
    PubMed     Abstract available
    
    
    
81. SATO K, Miura T, Sakamoto Y, Morohashi H, et al
    Fascial Organisation and Lymphatic Systems Around the Pelvic Floor: A Literature Review.
    Anticancer Res. 2021;41:4705-4714.
    PubMed     Abstract available
    
    
    
82. IIDA T, Murono K, Shiratori H, Nozawa H, et al
    Impact of Inferior Mesenteric Artery Occlusion on the Calibre of Collateral Arteries of the Colon.
    Anticancer Res. 2021;41:5189-5193.
    PubMed     Abstract available
    
    
    
83. CHUNG YC, Ku YL, Chiang HC, Liu WC, et al
    Antibody to Interleukin-6 Receptor Inhibits In Vivo Growth of Human Colorectal Carcinoma Cell Xenografts.
    Anticancer Res. 2021;41:4907-4916.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: